ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
Phase I Clinical and Pharmacokinetic Evaluation of the Vascular-Disrupting Agent OXi4503 in Patients with Advanced Solid Tumors
Clinical Cancer Research
◽
10.1158/1078-0432.ccr-11-2414
◽
2012
◽
Vol 18
(5)
◽
pp. 1415-1425
◽
Cited By ~ 55
Author(s):
Dan M. Patterson
◽
Martin Zweifel
◽
Mark R. Middleton
◽
Patricia M. Price
◽
Lisa K. Folkes
◽
...
Keyword(s):
Phase I
◽
Solid Tumors
◽
Advanced Solid Tumors
◽
Vascular Disrupting Agent
◽
Vascular Disrupting
◽
Pharmacokinetic Evaluation
Download Full-text
Related Documents
Cited By
References
Phase I Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Vascular Disrupting Agent Ombrabulin (AVE8062) in Patients with Advanced Solid Tumors
Clinical Cancer Research
◽
10.1158/1078-0432.ccr-13-0427
◽
2013
◽
Vol 19
(17)
◽
pp. 4832-4842
◽
Cited By ~ 32
Author(s):
Cristiana Sessa
◽
Patricia Lorusso
◽
Anthony Tolcher
◽
Françoise Farace
◽
Nathalie Lassau
◽
...
Keyword(s):
Phase I
◽
Solid Tumors
◽
Advanced Solid Tumors
◽
Vascular Disrupting Agent
◽
Vascular Disrupting
Download Full-text
A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors
Cancer Chemotherapy and Pharmacology
◽
10.1007/s00280-011-1565-4
◽
2011
◽
Vol 68
(4)
◽
pp. 959-970
◽
Cited By ~ 12
Author(s):
Alejandro D. Ricart
◽
Edward A. Ashton
◽
Matthew M. Cooney
◽
John Sarantopoulos
◽
Joanna M. Brell
◽
...
Keyword(s):
Phase I
◽
Solid Tumors
◽
Phase I Study
◽
Advanced Solid Tumors
◽
Vascular Disrupting Agent
◽
Vascular Disrupting
Download Full-text
Phase I Study of Ombrabulin, a Vascular Disrupting Agent (VDA), Administered Every 3 Weeks to Japanese Patients with Advanced Solid Tumors
Annals of Oncology
◽
10.1016/s0923-7534(20)32295-x
◽
2012
◽
Vol 23
◽
pp. xi110
Author(s):
T. Kurata
◽
H. Murakami
◽
Y. Fujisaka
◽
H. Kiyota
◽
H. Hayashi
◽
...
Keyword(s):
Phase I
◽
Solid Tumors
◽
Phase I Study
◽
Japanese Patients
◽
Advanced Solid Tumors
◽
Vascular Disrupting Agent
◽
Vascular Disrupting
Download Full-text
Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors
Cancer Research and Treatment
◽
10.4143/crt.2014.258
◽
2016
◽
Vol 48
(1)
◽
pp. 28-36
◽
Cited By ~ 17
Author(s):
Do-Youn Oh
◽
Tae-Min Kim
◽
Sae-Won Han
◽
Dong-Yeop Shin
◽
Yun Gyoo Lee
◽
...
Keyword(s):
Phase I
◽
Solid Tumors
◽
Phase I Study
◽
Advanced Solid Tumors
◽
Vascular Disrupting Agent
◽
Vascular Disrupting
Download Full-text
Abstract A15: A phase I and pharmacokinetic study of the vascular disrupting agent AVE8062 in combination with docetaxel, administered once every 3 weeks to patients with advanced solid tumors
10.1158/1535-7163.targ-09-a15
◽
2009
◽
Author(s):
Patricia Tresca
◽
Diego Tosi
◽
Leni Van Doorn
◽
Helene Fontaine
◽
Ate Van der Gaast
◽
...
Keyword(s):
Phase I
◽
Solid Tumors
◽
Pharmacokinetic Study
◽
Advanced Solid Tumors
◽
Vascular Disrupting Agent
◽
Vascular Disrupting
Download Full-text
Phase I pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent OXi4503 in patients with advanced solid tumors.
Journal of Clinical Oncology
◽
10.1200/jco.2010.28.15_suppl.2594
◽
2010
◽
Vol 28
(15_suppl)
◽
pp. 2594-2594
◽
Cited By ~ 3
Author(s):
M. Zweifel
◽
D. M. Patterson
◽
A. R. Padhani
◽
M. R. Middleton
◽
P. Price
◽
...
Keyword(s):
Phase I
◽
Solid Tumors
◽
Advanced Solid Tumors
◽
Vascular Disrupting Agent
◽
Vascular Disrupting
Download Full-text
Phase I and pharmacologic study of the vascular disrupting agent ombrabulin (Ob) combined with docetaxel (D) in patients (pts) with advanced solid tumors.
Journal of Clinical Oncology
◽
10.1200/jco.2010.28.15_suppl.3023
◽
2010
◽
Vol 28
(15_suppl)
◽
pp. 3023-3023
◽
Cited By ~ 6
Author(s):
P. Tresca
◽
D. Tosi
◽
L. van Doorn
◽
H. Fontaine
◽
A. V. Gaast
◽
...
Keyword(s):
Phase I
◽
Solid Tumors
◽
Advanced Solid Tumors
◽
Vascular Disrupting Agent
◽
Vascular Disrupting
◽
Pharmacologic Study
Download Full-text
Abstract C20: Phase I study of ombrabulin, a vascular disrupting agent (VDA), administered every 3 weeks to Japanese patients with advanced solid tumors.
10.1158/1535-7163.targ-11-c20
◽
2011
◽
Cited By ~ 1
Author(s):
Takayasu Kurata
◽
Haruyasu Murakami
◽
Yasuhito Fujisaka
◽
Hidemi Kiyota
◽
Kazuhiko Nakagawa
◽
...
Keyword(s):
Phase I
◽
Solid Tumors
◽
Phase I Study
◽
Japanese Patients
◽
Advanced Solid Tumors
◽
Vascular Disrupting Agent
◽
Vascular Disrupting
Download Full-text
386 Phase I study of the vascular disrupting agent (VDA) ombrabulin (Ob) in combination with taxanes (T) and platinum salts (PS) in patients (pts) with advanced solid tumors
European Journal of Cancer Supplements
◽
10.1016/s1359-6349(10)72093-0
◽
2010
◽
Vol 8
(7)
◽
pp. 122-123
◽
Cited By ~ 2
Author(s):
J.C. Soria
◽
R. Bahleda
◽
B. Besse
◽
C. Sessa
◽
R.g. Calderone
◽
...
Keyword(s):
Phase I
◽
Solid Tumors
◽
Phase I Study
◽
Advanced Solid Tumors
◽
Vascular Disrupting Agent
◽
Platinum Salts
◽
Vascular Disrupting
Download Full-text
Clinical, Pharmacodynamic, and Pharmacokinetic Evaluation of BNC105P: A Phase I Trial of a Novel Vascular Disrupting Agent and Inhibitor of Cancer Cell Proliferation
Clinical Cancer Research
◽
10.1158/1078-0432.ccr-11-0937
◽
2011
◽
Vol 17
(15)
◽
pp. 5152-5160
◽
Cited By ~ 34
Author(s):
Danny Rischin
◽
David C. Bibby
◽
Geoff Chong
◽
Gabriel Kremmidiotis
◽
Annabell F. Leske
◽
...
Keyword(s):
Cell Proliferation
◽
Phase I
◽
Cancer Cell
◽
Phase I Trial
◽
Cancer Cell Proliferation
◽
Vascular Disrupting Agent
◽
Vascular Disrupting
◽
Pharmacokinetic Evaluation
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close